Kaletra (Lopinavir/Ritonavir): Research
- Kaletra: Abbott Joins the Bandwagon (Spring 2001)
Recap of Kaletra's Phase III trial results and expanded access program.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Head-to-Head Study of Two Protease Inhibitors (March 2001)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
On TheBodyPRO.com
- Lopinavir (Kaletra) Update: Study M97-765 (September 2000)
In Research Initiative/Treatment Action!, from The Center for AIDS
- Lopinavir/Ritonavir (Norvir) Plus Either Efavirenz (Sustiva) or Nevirapine (Viramune) and Two NRTIs (Autumn 2000)
Highlights from the XIII International AIDS Conference.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- New Drugs in Development (Fall 2000)
Lopinavir (Kaletra; ABT-378/r).
In CRIA Update, from AIDS Community Research Initiative of America
- Kaletra™ (ABT-378/r) Early Access Program Can Accept More Patients (August 18, 2000)
More patients can now receive this experimental protease inhibitor.
In AIDS Treatment News, from AIDS Treatment News
- ABT-378/Ritonavir and Efavirenz for Salvage Therapy in Patients Multiply-Exposed to PIs (July 11, 2000)
In The XIII International AIDS Conference, from TheBodyPRO.com
- Kaletra™ (ABT-378/r) Application for Accelerated Approval (June 23, 2000)
Overview of new protease inhibitor moving toward wider use.
In AIDS Treatment News, from AIDS Treatment News
- Lopinavir: The Most Potent Protease Inhibitor (Summer 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Expanded Access Program for ABT-378/r Amended (May 2000)
In Positive Living, from AIDS Project Los Angeles
- Lopinavir Shows Good Activity (April 2000)
In Project Inform Perspective, from Project Inform
- Selected Highlights From the 7th CROI: ABT-378 (Lopinavir) Plus Ritonavir, d4T, and 3TC (Spring 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Abbott Expands ABT-378/Ritonavir Early-Access Program (February 2000)
In Positive Living, from AIDS Project Los Angeles
- ABT-378 "Early Access" Program (December 1999)
In Body Positive, from Body Positive
- Treatment News: Expanded Access Program for ABT-378 Under Way (November 1999)
Triangle Pharma Coactinon combo may suppress HIV.
In Positive Living, from AIDS Project Los Angeles
- ABT-378 Early Access Program Begins (October 1, 1999)
From AIDS Treatment News
- ABT-378: Abbott "Second Generation" Protease Inhibitor (February 21, 1997)
In AIDS Treatment News, from AIDS Treatment News
- ABT-378: A New Protease Inhibitor From Abbott (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- More Data on Higher-Dose Lopinavir/Ritonavir (July 13, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
